State Street Corp Raises Stake in Harrow, Inc. (NASDAQ:HROW)

State Street Corp raised its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 2.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 730,973 shares of the company’s stock after purchasing an additional 15,554 shares during the period. State Street Corp owned approximately 2.06% of Harrow worth $32,865,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Braidwell LP raised its position in Harrow by 47.9% in the third quarter. Braidwell LP now owns 439,638 shares of the company’s stock worth $19,766,000 after acquiring an additional 142,450 shares during the period. First Turn Management LLC bought a new position in shares of Harrow during the 3rd quarter valued at approximately $14,683,000. Rice Hall James & Associates LLC lifted its position in Harrow by 23.1% during the third quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company’s stock valued at $14,157,000 after purchasing an additional 59,019 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Harrow by 195.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock worth $11,313,000 after buying an additional 166,602 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Harrow during the 3rd quarter valued at about $8,572,000. Institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Lake Street Capital upped their price objective on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Craig Hallum boosted their price target on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley lowered their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $34.22 on Friday. The company has a 50 day simple moving average of $44.55 and a two-hundred day simple moving average of $36.65. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -36.40 and a beta of 0.69. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 12 month low of $9.13 and a 12 month high of $59.23.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.